Remibrutinib Beneficial for Urticaria After H1-Antihistamine Treatment

Follow Drugslib on

Medically reviewed by Carmen Pope, BPharm. Last updated on March 11, 2025.

By Elana Gotkine HealthDay Reporter

TUESDAY, March 11, 2025 -- For patients with symptomatic chronic spontaneous urticaria after treatment with second-generation H1-antihistamines, administration of the oral, highly selective Bruton's tyrosine kinase inhibitor, remibrutinib, results in a significant improvement in a composite measure of itching and hives at week 12, according to a study published in the March 6 issue of the New England Journal of Medicine.

Martin Metz, M.D., from Charité–Universitätsmedizin Berlin, and colleagues examined the efficacy and safety of remibrutinib in patients with symptomatic chronic spontaneous urticaria after treatment with second-generation H1-antihistamines in the identical REMIX-1 and REMIX-2 trials. Patients were randomly assigned to receive remibrutinib at a dose of 25 mg twice daily or placebo (313 and 157 patients, respectively, in REMIX-1; 300 and 155 patients, respectively, in REMIX-2). The change from baseline to week 12 in the urticaria activity score during a seven-day period (UAS7), which is composed of severity scores for itch and hives during one week, was assessed as the primary end point.

The researchers found that compared with the placebo group, the remibrutinib group had a significantly greater decrease in the UAS7 at week 12, which was sustained at week 24. Significantly more patients in the remibrutinib group versus the placebo group had a UAS7 score of 6 or lower at week 12 (REMIX-1: 49.8 versus 24.8 percent; REMIX-2: 46.8 versus 19.6 percent) and a UAS7 score of 0 (REMIX-1: 31.1 versus 10.5 percent; REMIX-2: 27.9 versus 6.5 percent). Adverse event rates were similar in the remibrutinib group and the placebo group, although petechiae were reported in a higher percentage of patients in the remibrutinib group than in the placebo group.

"These results support the efficacy and safety of remibrutinib in patients with chronic spontaneous urticaria that remained symptomatic despite treatment with second-generation H1-antihistamines," the authors write.

The study was funded by Novartis, the manufacturer of remibrutinib.

Abstract/Full Text (subscription or payment may be required)

Disclaimer: Statistical data in medical articles provide general trends and do not pertain to individuals. Individual factors can vary greatly. Always seek personalized medical advice for individual healthcare decisions.

Source: HealthDay

Posted : 2025-03-12 06:00

Read more

Disclaimer

Every effort has been made to ensure that the information provided by Drugslib.com is accurate, up-to-date, and complete, but no guarantee is made to that effect. Drug information contained herein may be time sensitive. Drugslib.com information has been compiled for use by healthcare practitioners and consumers in the United States and therefore Drugslib.com does not warrant that uses outside of the United States are appropriate, unless specifically indicated otherwise. Drugslib.com's drug information does not endorse drugs, diagnose patients or recommend therapy. Drugslib.com's drug information is an informational resource designed to assist licensed healthcare practitioners in caring for their patients and/or to serve consumers viewing this service as a supplement to, and not a substitute for, the expertise, skill, knowledge and judgment of healthcare practitioners.

The absence of a warning for a given drug or drug combination in no way should be construed to indicate that the drug or drug combination is safe, effective or appropriate for any given patient. Drugslib.com does not assume any responsibility for any aspect of healthcare administered with the aid of information Drugslib.com provides. The information contained herein is not intended to cover all possible uses, directions, precautions, warnings, drug interactions, allergic reactions, or adverse effects. If you have questions about the drugs you are taking, check with your doctor, nurse or pharmacist.

Popular Keywords